HUGHES, B.; GROB, J.-J. .; BOWYER, S.; DAY, F. .; LADWA, R.; STEIN, B. .; MUÑOZ-COUSELO, E.; BASSET-SEGUIN, N.; GUMINSKI, A. .; MORTIER, L. .; HAUSCHILD, A. .; MIGDEN, M. .; SCHMULTS, C. .; YOO, S.-Y.; BOOTH, J. .; SEEBACH, F. .; LOWY, I. .; FURY, M.; RISCHIN, D. . Phase 2 confirmatory study of cemiplimab (350 mg IV Q3W) in patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Study 1540 Group 6. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 2, p. s175, 2023. DOI: 10.25251/skin.7.supp.175. Disponível em: https://jofskin.org/33014/index.php/skin/article/view/1999. Acesso em: 4 jul. 2024.